Logotipo del repositorio
  • Español
  • English
  • Iniciar sesión
    Ayuda

    Instrucciones:

    El Repositorio Institucional Académico (RIA) de la Universidad Andrés Bello, es un recurso de acceso abierto. No obstante, y de acuerdo con la ley chilena vigente sobre propiedad intelectual, mantiene en acceso restringido diversos documentos, los cuales sólo pueden ser consultados por la comunidad universitaria registrada. Para poder acceder a éstos, verificar el tipo de usuario y método de acceso, siguiendo las instrucciones que se detallan a continuación:

    • Si eres investigador, docente o funcionario con correo @unab.cl, ingresa utilizando tu usuario de computador o intranet (nombre de usuario sin incluir @unab.cl) y clave.
    • Si eres alumno, profesor adjunto o exalumno con correo @uandresbello.edu, debes registrarte primero, pinchando donde dice Nuevo usuario. Una vez registrado y obtenida el alta, ingresa con el correo electrónico institucional y la clave elegida. El registro se debe realizar utilizando la cuenta de correo institucional, no serán válidas cuentas gmail, hotmail o cualquier otro proveedor.
    • Si eres usuario externo, contactar directamente a repositorio@unab.cl
    o
    ¿Nuevo Usuario? Pulse aquí para registrarse¿Has olvidado tu contraseña?
  • Comunidades
  • Todo RIA
  • Contacto
  • Procedimientos de publicaciónDerecho de autorPolíticas del Repositorio
  1. Inicio
  2. Buscar por autor

Examinando por Autor "Fernández, D."

Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
  • Cargando...
    Miniatura
    Ítem
    In vitro-generated Tc17 cells present a memory phenotype and serve as a reservoir of Tc1 cells in vivo
    (Frontiers Media, 2018-02) Flores-Santibáñez, F.; Cuadra, B.; Fernández, D.; Rosemblatt, M.V.; Núñez, S.; Cruz, P.; Gálvez-Cancino, F.; César Cárdenas, J.; Lladser, A.; Rosemblatt, M.; Bono, M.R.; Sauma, D.
    Memory CD8+ T cells are ideal candidates for cancer immunotherapy because they can mediate long-term protection against tumors. However, the therapeutic potential of different in vitro-generated CD8+ T cell effector subsets to persist and become memory cells has not been fully characterized. Type 1 CD8+ T (Tc1) cells produce interferon-γ and are endowed with high cytotoxic capacity, whereas IL-17-producing CD8+ T (Tc17) cells are less cytotoxic but display enhanced self-renewal capacity. We sought to evaluate the functional properties of in vitro-generated Tc17 cells and elucidate their potential to become long lasting memory cells. Our results show that in vitro-generated Tc17 cells display a greater in vivo persistence and expansion in response to secondary antigen stimulation compared to Tc1 cells. When transferred into recipient mice, Tc17 cells persist in secondary lymphoid organs, present a recirculation behavior consistent with central memory T cells, and can shift to a Tc1 phenotype. Accordingly, Tc17 cells are endowed with a higher mitochondrial spare respiratory capacity than Tc1 cells and express higher levels of memory-related molecules than Tc1 cells. Together, these results demonstrate that in vitro-generated Tc17 cells acquire a central memory program and provide a lasting reservoir of Tc1 cells in vivo, thus supporting the use of Tc17 lymphocytes in the design of novel and more effective therapies.
  • Cargando...
    Miniatura
    Ítem
    The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells
    (Nature Research, 2021-12) Doñas, C.; Neira, J.; Osorio-Barrios, F.; Carrasco, M.; Fernández, D.; Prado, C.; Loyola, A.; Pacheco, R.; Rosemblatt, M.
    Dendritic cells (DCs) promote T-cell mediated tolerance to self-antigens and induce inflammation to innocuous-antigens. This dual potential makes DCs fundamental players in inflammatory disorders. Evidence from inflammatory colitis mouse models and inflammatory bowel diseases (IBD) patients indicated that gut inflammation in IBD is driven mainly by T-helper-1 (Th1) and Th17 cells, suggesting an essential role for DCs in the development of IBD. Here we show that GSK-J4, a selective inhibitor of the histone demethylase JMJD3/UTX, attenuated inflammatory colitis by reducing the inflammatory potential and increasing the tolerogenic features of DCs. Mechanistic analyses revealed that GSK-J4 increased activating epigenetic signals while reducing repressive marks in the promoter of retinaldehyde dehydrogenase isoforms 1 and 3 in DCs, enhancing the production of retinoic acid. This, in turn, has an impact on regulatory T cells (Treg) increasing their lineage stability and gut tropism as well as potentiating their suppressive activity. Our results open new avenues for the treatment of IBD patients. © 2021, The Author(s).